Biosimilar Monoclonal Antibodies Market

Monoclonal antibodies (mAb) are antibodies produced by using identical immune cells that are clones of one unique parent cell. Since monoclonal antibodies are produced from clones of only one parent cell, all monoclonal antibodies produced by the parent cell are the same due to which, they are called biosimilar monoclonal antibodies.

Biosimilar Monoclonal Antibodies refer to the biologic medical product that are almost an identical copy of the original monoclonal antibodies but manufactured by a different company.

Biosimilar Monoclonal Antibodies Market contains market size and forecasts of Biosimilar Monoclonal Antibodies in global, including the following market information:

Global Biosimilar Monoclonal Antibodies Market Revenue, 2017-2022, 2023-2028, ($ millions)

Global Biosimilar Monoclonal Antibodies Market Sales, 2017-2022, 2023-2028, (K Units)

Global top five Biosimilar Monoclonal Antibodies companies in 2021 (%)

The global Biosimilar Monoclonal Antibodies market was valued at 4639.7 million in 2021 and is projected to reach US$ 12580 million by 2028, at a CAGR of 15.3% during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

Infliximab Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Biosimilar Monoclonal Antibodies include Celltrion, Pfizer (Hospira), 3SBIO, Novartis (Sandoz), Dr Reddy?s, Celgen Biopharma, Cadila Healthcare, Hisun Pharma and Torrent Pharmaceuticals. etc. In 2021, the global top five players have a share approximately % in terms of revenue.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Biosimilar Monoclonal Antibodies manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Biosimilar Monoclonal Antibodies Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (K Units)

Global Biosimilar Monoclonal Antibodies Market Segment Percentages, by Type, 2021 (%)

• Infliximab
• Rituximab
• Trastuzumab
• Adalimumab
• Other

Global Biosimilar Monoclonal Antibodies Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (K Units)

Global Biosimilar Monoclonal Antibodies Market Segment Percentages, by Application, 2021 (%)

• Oncology
• Autoimmune Disease
• Other

Global Biosimilar Monoclonal Antibodies Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (K Units)

Global Biosimilar Monoclonal Antibodies Market Segment Percentages, By Region and Country, 2021 (%)

• North America
• US
• Canada
• Mexico
• Europe
• Germany
• France
• U.K.
• Italy
• Russia
• Nordic Countries
• Benelux
• Rest of Europe
• Asia
• China
• Japan
• South Korea
• Southeast Asia
• India
• Rest of Asia
• South America
• Brazil
• Argentina
• Rest of South America
• Middle East & Africa
• Turkey
• Israel
• Saudi Arabia
• UAE
• Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

• Key companies Biosimilar Monoclonal Antibodies revenues in global market, 2017-2022 (Estimated), ($ millions)
• Key companies Biosimilar Monoclonal Antibodies revenues share in global market, 2021 (%)
• Key companies Biosimilar Monoclonal Antibodies sales in global market, 2017-2022 (Estimated), (K Units)
• Key companies Biosimilar Monoclonal Antibodies sales share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

• Celltrion
• Pfizer (Hospira)
• 3SBIO
• Novartis (Sandoz)
• Dr Reddy?s
• Celgen Biopharma
• Cadila Healthcare
• Hisun Pharma
• Torrent Pharmaceuticals